AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Lipoprotein lipase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P06858

UPID:

LIPL_HUMAN

Alternative names:

Phospholipase A1

Alternative UPACC:

P06858; B2R5T9; Q16282; Q16283; Q96FC4

Background:

Lipoprotein lipase, also known as Phospholipase A1, is a pivotal enzyme in triglyceride metabolism. It catalyzes the hydrolysis of triglycerides in chylomicrons and VLDL, facilitating lipid clearance, utilization, and storage. This enzyme is essential for lipid metabolism, with activities primarily focused on triglyceride lipase and minor phospholipase functions. It is recruited to vascular endothelium surfaces, playing a critical role in lipid transport within the bloodstream.

Therapeutic significance:

Lipoprotein lipase's dysfunction is linked to Hyperlipoproteinemia 1 and Familial Combined Hyperlipidemia 3, both metabolic disorders characterized by abnormal lipid levels and increased risk of coronary heart disease. Understanding the enzyme's role could lead to novel therapeutic strategies targeting these lipid metabolism disorders, potentially offering new avenues for treatment and management of related cardiovascular diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.